Janus kinase

From Proteopedia

proteopedia linkproteopedia link

spinqualitylabelsall models JAK2 kinase domain complex with inhibitor thienopyridine 3tjc Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Contents 1 Function 2 Relevance 3 Disease 4 Structural highlights Function Janus kinase (JAK) are nonreceptor tyrosine kinases which transduces cytokine-mediated signals via the JAK-STAT pathway. The JAK-STAT pathway transmits signals through the cell membrane to DNA promoters thus causing transcription. The name JAK is derived from Just Another Kinase. JAK proteins contain 2 phosphate-transfer domains, one with kinase activity using a phosphotyrosine (PTyr) and the other a pseudokinase domain which negatively regulates the kinase domain. JAK contains seven Janus homology domains named JH1-7. JAK family members are JAK1, JAK2, JAK3 and TYK2[1]. JAK1 and TYK2 are involved in signaling by members of type I and type II cytokine receptors. JAK2 is involved in signaling by members of the interferon receptors (type II cytokines). JAK3 is predominantly active in immune cells. JAK3 is activated by cytokines whose receptors contain the common γ chain subunit (interleukin 2,4,7,9,15,21). TYK2 is a component of type I and type III interferon signaling pathways. See Tyrosine kinase. Relevance Jak3 inhibitors are tested in treatment of autoimmune diseases and transplant rejection[2]. Disease Mutations in Jak2 are associated with chronic myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis[3]. Mutations in Jak3 are associated with immune deficiency. Structural highlights Jak2 containing binds the in the ATP-binding pocket[4]. Water molecules shown as red spheres.

3D Structures of Janus kinase

Updated on 23-July-2018 {{#tree:id=OrganizedByTopic|openlevels=0|

• JAK1 kinase domain

• • 4e4l, 4e4n, 4e5w, 4ehz, 4ei4, 4fk6, 4i5c, 4k6z, 3eyg, 3eyh, 5e1e, 5hx8, 5khx – hJAK1 kinase domain + PTyr + inhibitor - human
    
  • 5khw – hJAK1 kinase domain + PTyr + ADP
    

• JAK1 JH1 domain

• • 4k77 – hJAK1 JH1 domain + PTyr + inhibitor
    

• JAK1 pseudokinase domain
  • 4l00 – hJAK1 pseudokinase domain
    
  • 4l01 – hJAK1 pseudokinase domain (mutant)
    

• JAK1 FERM-SH2 domain

• • 5ixd, 5l04 – hJAK1 + IFN l receptor
    
  • 5ixi – hJAK1 + IFN l receptor/IL10
    

• JAK2 kinase domain

• • 4fvp - hJAK2 kinase domain
    
  • 2b7a, 3fup, 4e6d, 4e6q, 4f08 – hJAK2 kinase domain (mutant) + PTyr + inhibitor
    
  • 3ugc, 4bbe, 4bbf, 3zmm, 2xa4, 4c61, 4c62, 5l3a, 5tq3, 5tq4, 5tq5, 5tq6, 5tq7, 5tq8 – hJAK2 kinase domain (mutant) + inhibitor
    
  • 3e62, 3e63, 3e64, 2w1i, [[3i4ytc, 4ytf, 4yth, 4yti, 4zim, 5aep, 5cf4, 5cf5, 5cf6, 3io7, 3iok, 3kck, 3jy9, 3lpb, 3krr, 3q32, 3tjc, 3tjd, 3rvg, 4aqc, 4e4m, 4f09, 4hge, 4d0w, 4d0x, 4d1s, 4p7e, 4aep, 4ytc, 4ytf, 4yth, 4yti, 4zim, 5aep, 5cf4, 5cf5, 5cf6, 5cf8 – hJAK2 kinase domain + PTyr + inhibitor
    
  • 4gl9 – mJAK2 kinase domain + PTyr + inhibitor + suppressor of cytokine signaling 3 + interleukin 6 receptor subunit β - mouse
    

• JAK2 JH1 domain

• • 4gfm, 4gmy, 4iva, 4ivb, 4ivc, 4ivd, 4ji9, 4jia, 5usy, 5usz, 5ut0, 5ut1, 5ut2, 5ut3, 5ut4, 5ut5, 5ut6 - hJAK2 JH1 domain + PTyr + inhibitor
    
  • 5hez - hJAK2 JH1 domain (mutant) + PTyr + inhibitor
    

• JAK2 pseudokinase domain

• • 3ugc – hJAK2 pseudokinase domain (mutant)
    
  • 4fvq, 4fvr, 5i4n – hJAK2 pseudokinase domain (mutant) + ATP
    

• JAK2 FERM-SH2 domain

• • 4z32 – hJAK2
    

• JAK3 kinase domain

• • 1yvj – hJAK3 kinase domain (mutant) + PTyr + staurosporine analog
    
  • 3lxk, 3lxl – hJAK3 kinase domain (mutant) + PTyr + inhibitor
    
  • 3pjc, 4v0g, 4z16, 5lwm, 5lwn, 5toz – hJAK3 kinase domain + inhibitor
    
  • 4hvd, 4hvg, 4hvh, 4hvi, 3zc6, 3zep, 4i6q, 4qps, 4rio, 4qt1, 5tts, 5ttu, 5ttv, 5vo6 – hJAK3 kinase domain (mutant) + inhibitor
    

• TYK2 see Tyrosine kinase

}}

References

1. ↑ Liu KD, Gaffen SL, Goldsmith MA, Greene WC. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr Biol. 1997 Nov 1;7(11):817-26. PMID:9382798
2. ↑ O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii111-5. doi: 10.1136/annrheumdis-2012-202576. PMID:23532440 doi:http://dx.doi.org/10.1136/annrheumdis-2012-202576
3. ↑ Levine RL. Janus kinase mutations. Semin Oncol. 2009 Apr;36(2 Suppl 1):S6-11. doi: 10.1053/j.seminoncol.2009.02.005. PMID:19393837 doi:http://dx.doi.org/10.1053/j.seminoncol.2009.02.005
4. ↑ Schenkel LB, Huang X, Cheng A, Deak HL, Doherty E, Emkey R, Gu Y, Gunaydin H, Kim JL, Lee J, Loberg R, Olivieri P, Pistillo J, Tang J, Wan Q, Wang HL, Wang SW, Wells MC, Wu B, Yu V, Liu L, Geuns-Meyer S. Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors. J Med Chem. 2011 Nov 16. PMID:22087750 doi:10.1021/jm200911r